Thyroid cancer with toxic goiter
Abstract
Recently, thyroid
cancer (TC) has been very often detected in patients operated on for Graves’
disease (GD). There is no clear data on the frequency and risk factors for the
development of thyroid cancer in operated patients with GD.
Aim of this study is to assess the risk of developing
thyroid cancer in patients with GD after surgical treatment.
Material and methods. The data of 121 patients with GD, after
thyreoidectomy at the center of endocrine Surgery in Krasnodar in the period from
2015 to 2020, was evaluated retrospectively. The diagnosis of thyroid cancer
was confirmed by the results of a pathoanatomic study. Thyroid cancer was
detected after thyroidectomy in 34 patients operated for GD (28.1%). During
preoperative ultrasound examination of the thyroid gland (ultrasound), nodular
goiter was diagnosed in 62 (51.2%) patients. Nodular formations were not found
in other 59 (48.8%) patients with GD.
Results. The frequency of thyroid cancer was significantly
higher in patients with nodular formations (38 vs 16%; p=0.009). In 32
of 34 cases, papillary thyroid cancer (PTC) was detected, and in the remaining
two cases follicular thyroid cancer. Of the 32 patients with PTC, 28 were of
the classical type, and 2 patients had a follicular variant of papillary
cancer, 1 – oncocytic and 1 – columnar cell variant of PTC.
Conclusion. Risk of cancer was higher in patients with GD with
nodule. In addition to the main examination of patients with GD, ultrasound
examination was performed with examination of regional lymph nodes with further
determination of surgical tactics.
Keywords:Graves’ disease; thyroid cancer; thyroid node
Funding. The study had no sponsor support.
Conflict of interest. The author declares no conflict of interest.
For citation: Ryabchenko E.V. Thyroid cancer with toxic goiter.
Clinical and Experimental Surgery. Petrovsky Journal. 2023; 11 (1): 64–9. DOI: https://doi.org/10.33029/2308-1198-2023-11-1-64-69
(in Russian)
References
1. Burch H.B., Cooper D.S. Management of Graves’ disease: A review. JAMA. 2015; 314: 2544–54. DOI: https://doi.org/10.1001/jama.2015.16535
2. Vander J.B., Gaston E.A., Dawber T.R. The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. Ann Intern Med. 1968; 69: 537–40. DOI: https://doi.org/10.7326/0003-4819-69-3-537
3. Pellegriti G., Mannarino C., Russo M., et al. Increased mortality in patients with differentiated thyroid cancer associated with Graves’ disease. J Clin Endocrinol Metab. 2013; 14: 321–5. DOI: https://doi.org/10.1210/jc.2012-2843
4. Pacini F., Elisei R., Di Coscio G.C., et al. Thyroid carcinoma in thyrotoxic patients treated by surgery. J Endocrinol Invest. 1988; 11: 107–12. DOI: https://doi.org/10.1007/BF03350115
5. Gerenova J., Buysschaert M., de Burbure C.Y., Daumerie C. Prevalence of thyroid cancer in Graves’ disease: a retrospective study of a cohort of 103 patients treated surgically. Eur J Intern Med. 2003; 14: 321–5. DOI: https://doi.org/10.1016/s0953-6205(03)00105-5
6. Ozaki O., Ito K., Kobayashi K., Toshima K., Iwasaki H., Yashiro T. Thyroid carcinoma in Graves’ disease. World J Surg. 1990; 14: 437–40. DOI: https://doi.org/10.1007/BF01658550
7. Yano Y., Shibuya H., Kitagawa W., et al. Recent outcome of Graves’ disease patients with papillary thyroid cancer. Eur J Endocrinol. 2007; 157: 325–9. DOI: https://doi.org/10.1530/EJE-07-0136
8. Tamatea J.A., Tu’akoi K., Conaglen J.V., Elston M.S., Meyer-Rochow G.Y. Thyroid cancer in Graves’ disease: is surgery the best treatment for Graves’ disease? Aust N Z J Surg. 2014; 84: 231–4. DOI: https://doi.org/10.1111/j.1445-2197.2012.06233.x
9. Chao T.C., Lin J.D., Chen M.F. Surgical treatment of thyroid cancers with concurrent Graves’ disease. Ann Surg Oncol. 2004; 11: 407–12. DOI: https://doi.org/10.1245/ASO.2004.06.011
10. Weber K.J., Solorzano C.C., Lee J.K., Gaffud M.J., Prinz R.A. Thyroidectomy remains an effective treatment option for Graves’ disease. Am J Surg. 2006; 191: 400–5. DOI: https://doi.org/10.1016/j.amjsurg.2005.10.043
11. Phitayakorn R., McHenry C.R. Incidental thyroid carcinoma in patients with Graves’ disease. Am J Surg. 2008; 195: 292–7. DOI: https://doi.org/10.1016/j.amjsurg.2007.12.006
12. Boutzios G., Vasileiadis I., Zapanti E., et al. Higher incidence of tall cell variant of papillary thyroid carcinoma in Graves’ disease. Thyroid. 2014; 24: 347–54. DOI: https://doi.org/10.1089/thy.2013.0133
13. Wei S., Baloch Z.W., LiVolsi V.A. Thyroid carcinoma in patients with Graves’ disease: an institutional experience. Endocr Pathol. 2015; 26: 48–53. DOI: https://doi.org/10.1007/s12022-014-9343-6
14. Gabriele R., Letizia C., Borghese M., et al. Thyroid cancer in patients with hyperthyroidism. Horm Res. 2003; 60: 79–83. DOI: https://doi.org/10.1159/000071875
15. Filetti S., Belfiore A., Amir S.M., et al. The role of thyroid-stimulating antibodies of Graves’ disease in differentiated thyroid cancer. N Engl J Med. 1988; 318: 753–9. DOI: https://doi.org/10.1056/NEJM198803243181206
16. Belfiore A., Russo D., Vigneri R., Filetti S. Graves’ disease, thyroid nodules and thyroid cancer. Clin Endocrinol. 2001; 55: 711–8. DOI: https://doi.org/10.1046/j.1365-2265.2001.01415.x
17. Tam A.A., Kaya C., Kilic F.B., Ersoy R., Cakir B. Thyroid nodules and thyroid cancer in Graves’ disease. Arq Bras Endocrinol Metabol. 2014; 58: 933–8. DOI: https://doi.org/10.1590/0004-2730000003569
18. Ren M., Wu M.C., Shang C.Z., et al. Predictive factors of thyroid cancer in patients with Graves’ disease. World J Surg. 2014; 38: 80–7. DOI: https://doi.org/10.1007/s00268-013-2287-z
19. Staniforth J.U., Erdirimanne S., Eslick G.D. Thyroid carcinoma in Graves’ disease: A meta-analysis. Int J Surg. 2016; 27: 118–25. DOI: https://doi.org/10.1016/j.ijsu.2015.11.027
20. Erbil Y., Barbaros U., Ozbey N., et al. Graves’ disease, with and without nodules, and the risk of thyroid carcinoma. J Laryngol Otol. 2008; 122: 291–5. DOI: https://doi.org/10.1017/S0022215107000448
21. Kaczka K.A., Pomorski L. One-step nucleic acid amplification analysis of sentinel lymph nodes in papillary thyroid cancer patients. Arch Med Sci. 2017; 13: 1416–26. DOI: https://doi.org/10.5114/aoms.2017.65466
22. Hales I.B., McElduff A., Crummer P., et al. Does Graves’ disease or thyrotoxicosis affect the prognosis of thyroid cancer. J Clin Endocrinol Metab. 1992; 75: 886–9. DOI: https://doi.org/10.1210/jcem.75.3.1517381
23. Belfiore A., Garofalo M.R., Giuffrida D., et al. Increased aggressiveness of thyroid cancer in patients with Graves’ disease. J Clin Endocrinol Metab. 1990; 70: 830–5. DOI: https://doi.org/10.1210/jcem-70-4-830
24. Pellegriti G., Belfiore A., Giuffrida D., Lupo L., Vigneri R. Outcome of differentiated thyroid cancer in Graves’ patients. J Clin Endocrinol Metabol. 1998; 83: 2805–9. DOI: https://doi.org/10.1210/jcem.83.8.4997
25. Ergin A.B., Saralaya S., Olansky L. Incidental papillary thyroid carcinoma: clinical characteristics and prognostic factors among patients with Graves’ disease and euthyroid goiter, Cleveland Clinic experience. Am J Otolaryngol. 2014; 35: 784–90. DOI: https://doi.org/10.1016/j.amjoto.2014.04.013